TP53 hot spot mutations in ovarian cancer

Selective resistance to microtubule stabilizers in vitro and differential survival outcomes from the Cancer Genome Atlas

Brandon Luke L Seagle, Chia-Ping H. Yang, Kevin H. Eng, Monica Dandapani, Oluwatosin Odunsi-Akanji, Gary L. Goldberg, Kunle Odunsi, Susan Band Horwitz, Shohreh Shahabi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective To test if TP53 hot spot mutations (HSMs) confer differential chemotherapy resistance or survival outcomes, the effects of microtubule stabilizers on human ovarian carcinoma cells (OCCs) expressing TP53 HSMs were studied in vitro. Survival outcomes of patients with high grade serous epithelial ovarian carcinoma (HGS EOC) expressing matched HSMs were compared using The Cancer Genome Atlas (TCGA) data. Methods Growth inhibition of OCCs transfected with a HSM (m175, m248 or m273) was measured during treatment with paclitaxel, epothilone B (epoB), or ixabepilone. Effects of epoB on p53 expression, phosphorylation, and acetylation, as well as p53-regulated expression of p21 and mdm2 proteins, were determined by Western blot analysis. Expression of p53 target genes P21, GADD45, BAX, PIDD, NF-kB2, PAI-1, and MDR1 was measured by RT-PCR. cBioPortal.org identified patients with codon R175, R248 or R273 HSMs from TCGA data. Survival outcomes were characterized. Results p53-m248 confers chemoresistance and is not acetylated during epoB treatment. m273 demonstrated high MDR1 expression and resistance to paclitaxel. P21, GADD45 and PAI-1 expression were down-regulated in mutant OCCs. Optimally cytoreduced patients with codon R273 (n = 17), R248 (n = 13), R175 (n = 7) HSMs, or any other TP53 mutation demonstrated median 14.9, 17.6, 17.8 and 16.9 months (p = 0.806) progression free survival and 84.1, 33.6, 62.1 and 44.5 months (p = 0.040) overall survival, respectively. Conclusions Human OCCs harboring different TP53 HSMs were selectively resistant to microtubule stabilizers. Patients with different HSMs had significantly different overall survival. Both in vitro data and clinical experience support further studying the outcomes of particular TP53 HSMs.

Original languageEnglish (US)
Pages (from-to)159-164
Number of pages6
JournalGynecologic Oncology
Volume138
Issue number1
DOIs
StatePublished - Jul 1 2015

Fingerprint

Atlases
Microtubules
Ovarian Neoplasms
Genome
Mutation
Survival
Neoplasms
Carcinoma
Plasminogen Activator Inhibitor 1
Paclitaxel
Codon
Proto-Oncogene Proteins c-mdm2
In Vitro Techniques
p53 Genes
Acetylation
Disease-Free Survival
Western Blotting
Phosphorylation
Drug Therapy
Polymerase Chain Reaction

Keywords

  • Drug therapy
  • Ovarian neoplasms
  • Survival
  • TP53 genes

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

TP53 hot spot mutations in ovarian cancer : Selective resistance to microtubule stabilizers in vitro and differential survival outcomes from the Cancer Genome Atlas. / Seagle, Brandon Luke L; Yang, Chia-Ping H.; Eng, Kevin H.; Dandapani, Monica; Odunsi-Akanji, Oluwatosin; Goldberg, Gary L.; Odunsi, Kunle; Band Horwitz, Susan; Shahabi, Shohreh.

In: Gynecologic Oncology, Vol. 138, No. 1, 01.07.2015, p. 159-164.

Research output: Contribution to journalArticle

Seagle, Brandon Luke L ; Yang, Chia-Ping H. ; Eng, Kevin H. ; Dandapani, Monica ; Odunsi-Akanji, Oluwatosin ; Goldberg, Gary L. ; Odunsi, Kunle ; Band Horwitz, Susan ; Shahabi, Shohreh. / TP53 hot spot mutations in ovarian cancer : Selective resistance to microtubule stabilizers in vitro and differential survival outcomes from the Cancer Genome Atlas. In: Gynecologic Oncology. 2015 ; Vol. 138, No. 1. pp. 159-164.
@article{93bc66c9a71d45b7a26b28c5add4c4d4,
title = "TP53 hot spot mutations in ovarian cancer: Selective resistance to microtubule stabilizers in vitro and differential survival outcomes from the Cancer Genome Atlas",
abstract = "Objective To test if TP53 hot spot mutations (HSMs) confer differential chemotherapy resistance or survival outcomes, the effects of microtubule stabilizers on human ovarian carcinoma cells (OCCs) expressing TP53 HSMs were studied in vitro. Survival outcomes of patients with high grade serous epithelial ovarian carcinoma (HGS EOC) expressing matched HSMs were compared using The Cancer Genome Atlas (TCGA) data. Methods Growth inhibition of OCCs transfected with a HSM (m175, m248 or m273) was measured during treatment with paclitaxel, epothilone B (epoB), or ixabepilone. Effects of epoB on p53 expression, phosphorylation, and acetylation, as well as p53-regulated expression of p21 and mdm2 proteins, were determined by Western blot analysis. Expression of p53 target genes P21, GADD45, BAX, PIDD, NF-kB2, PAI-1, and MDR1 was measured by RT-PCR. cBioPortal.org identified patients with codon R175, R248 or R273 HSMs from TCGA data. Survival outcomes were characterized. Results p53-m248 confers chemoresistance and is not acetylated during epoB treatment. m273 demonstrated high MDR1 expression and resistance to paclitaxel. P21, GADD45 and PAI-1 expression were down-regulated in mutant OCCs. Optimally cytoreduced patients with codon R273 (n = 17), R248 (n = 13), R175 (n = 7) HSMs, or any other TP53 mutation demonstrated median 14.9, 17.6, 17.8 and 16.9 months (p = 0.806) progression free survival and 84.1, 33.6, 62.1 and 44.5 months (p = 0.040) overall survival, respectively. Conclusions Human OCCs harboring different TP53 HSMs were selectively resistant to microtubule stabilizers. Patients with different HSMs had significantly different overall survival. Both in vitro data and clinical experience support further studying the outcomes of particular TP53 HSMs.",
keywords = "Drug therapy, Ovarian neoplasms, Survival, TP53 genes",
author = "Seagle, {Brandon Luke L} and Yang, {Chia-Ping H.} and Eng, {Kevin H.} and Monica Dandapani and Oluwatosin Odunsi-Akanji and Goldberg, {Gary L.} and Kunle Odunsi and {Band Horwitz}, Susan and Shohreh Shahabi",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.ygyno.2015.04.039",
language = "English (US)",
volume = "138",
pages = "159--164",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - TP53 hot spot mutations in ovarian cancer

T2 - Selective resistance to microtubule stabilizers in vitro and differential survival outcomes from the Cancer Genome Atlas

AU - Seagle, Brandon Luke L

AU - Yang, Chia-Ping H.

AU - Eng, Kevin H.

AU - Dandapani, Monica

AU - Odunsi-Akanji, Oluwatosin

AU - Goldberg, Gary L.

AU - Odunsi, Kunle

AU - Band Horwitz, Susan

AU - Shahabi, Shohreh

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Objective To test if TP53 hot spot mutations (HSMs) confer differential chemotherapy resistance or survival outcomes, the effects of microtubule stabilizers on human ovarian carcinoma cells (OCCs) expressing TP53 HSMs were studied in vitro. Survival outcomes of patients with high grade serous epithelial ovarian carcinoma (HGS EOC) expressing matched HSMs were compared using The Cancer Genome Atlas (TCGA) data. Methods Growth inhibition of OCCs transfected with a HSM (m175, m248 or m273) was measured during treatment with paclitaxel, epothilone B (epoB), or ixabepilone. Effects of epoB on p53 expression, phosphorylation, and acetylation, as well as p53-regulated expression of p21 and mdm2 proteins, were determined by Western blot analysis. Expression of p53 target genes P21, GADD45, BAX, PIDD, NF-kB2, PAI-1, and MDR1 was measured by RT-PCR. cBioPortal.org identified patients with codon R175, R248 or R273 HSMs from TCGA data. Survival outcomes were characterized. Results p53-m248 confers chemoresistance and is not acetylated during epoB treatment. m273 demonstrated high MDR1 expression and resistance to paclitaxel. P21, GADD45 and PAI-1 expression were down-regulated in mutant OCCs. Optimally cytoreduced patients with codon R273 (n = 17), R248 (n = 13), R175 (n = 7) HSMs, or any other TP53 mutation demonstrated median 14.9, 17.6, 17.8 and 16.9 months (p = 0.806) progression free survival and 84.1, 33.6, 62.1 and 44.5 months (p = 0.040) overall survival, respectively. Conclusions Human OCCs harboring different TP53 HSMs were selectively resistant to microtubule stabilizers. Patients with different HSMs had significantly different overall survival. Both in vitro data and clinical experience support further studying the outcomes of particular TP53 HSMs.

AB - Objective To test if TP53 hot spot mutations (HSMs) confer differential chemotherapy resistance or survival outcomes, the effects of microtubule stabilizers on human ovarian carcinoma cells (OCCs) expressing TP53 HSMs were studied in vitro. Survival outcomes of patients with high grade serous epithelial ovarian carcinoma (HGS EOC) expressing matched HSMs were compared using The Cancer Genome Atlas (TCGA) data. Methods Growth inhibition of OCCs transfected with a HSM (m175, m248 or m273) was measured during treatment with paclitaxel, epothilone B (epoB), or ixabepilone. Effects of epoB on p53 expression, phosphorylation, and acetylation, as well as p53-regulated expression of p21 and mdm2 proteins, were determined by Western blot analysis. Expression of p53 target genes P21, GADD45, BAX, PIDD, NF-kB2, PAI-1, and MDR1 was measured by RT-PCR. cBioPortal.org identified patients with codon R175, R248 or R273 HSMs from TCGA data. Survival outcomes were characterized. Results p53-m248 confers chemoresistance and is not acetylated during epoB treatment. m273 demonstrated high MDR1 expression and resistance to paclitaxel. P21, GADD45 and PAI-1 expression were down-regulated in mutant OCCs. Optimally cytoreduced patients with codon R273 (n = 17), R248 (n = 13), R175 (n = 7) HSMs, or any other TP53 mutation demonstrated median 14.9, 17.6, 17.8 and 16.9 months (p = 0.806) progression free survival and 84.1, 33.6, 62.1 and 44.5 months (p = 0.040) overall survival, respectively. Conclusions Human OCCs harboring different TP53 HSMs were selectively resistant to microtubule stabilizers. Patients with different HSMs had significantly different overall survival. Both in vitro data and clinical experience support further studying the outcomes of particular TP53 HSMs.

KW - Drug therapy

KW - Ovarian neoplasms

KW - Survival

KW - TP53 genes

UR - http://www.scopus.com/inward/record.url?scp=84931560283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931560283&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2015.04.039

DO - 10.1016/j.ygyno.2015.04.039

M3 - Article

VL - 138

SP - 159

EP - 164

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -